Bridging the Gap: Conference Workbook [International Conference on AIDS (12th: 1994: Geneva, Switzerland)]

Tuesday, June 30

POSTER SSIONS Track B022377-22399

22377 A cohort study of the natural history of undetectable HIV RNA induced
by combination antiretroviral therapy
John Nienow*; T. Mitchell; C.C Child; T. Elbeik;J. Pannell; P. Bacchetti;
D.I. Abrams, USA
22378 Triple combination therapy with nevirapine in a clinical practice
Douglas Ward*; Douglas Ward; R.A. Elion; C.A. Owen, USA
22379 Measurement of adherence to clinical guidelines and patient outcomes:
Example of guidelines for antiretroviral therapy and chemoprophylaxis
in HIV+ disease
Deborah Marshall*; K. Simpson; P. Thompson, USA
22380 Penetrance of combination antiretroviral therapy into the Women's
Interagency HIV Study (WIHS)
Mardge Cohen*;J. Cook; H. Palacio; T. Wilson;J. Currier; M. Young, USA
22381 Are nelfinavir containing regimens effective as second line triple
therapy?
Enos Bernasconi*; Lorenzo Magenta; J.C. Piffaretti; A. Carota; M. Pons;
C. Bottarelli-Gandola; T. Mocetti; E. Bernasconi, Switzerland
22382 Same antiretroviral combination proves highly or poorly effective in
treatment-naive or AZT-Experienced HIV-1 infected adult patients
Adrien G. Saimot*; Jacques Leibowitch; D. Mathez; R. Landman;
C. Goujard; F. Damond; A.G. Saimot; The IMEA 01 and 02 Study Group,
France
22383 Quantitation of HIV biomolecular parameters in plasma and PBMCs in
naive patients with CD4+ T cells counts from 200 to 500/μl and
plasma RNA < 5000 copies ml during HAART (AZT, 3TC, Ind)
Maurizia Debiaggi*; S.F.A. Patruno; G. Barbarini; R. Bruno; F. Zara; E.
Romero; G. Filice, Italy
22384 Full compliance sustains viral suppression during tritherapy initiated at
primary HIV-1 infection
Catherine Tamalet*; I. Poizot Martin; N. Yahi; G. Lepeu; J. Moreau;
H. Gallais; J.A. Gaytaut, France
22385 Evolution of the antiretroviral prescription in France, from June 1994 to
September 1997
Sophie Courtial-Destembert*; J.M. Nadal; F. Bourdillon; L. Cavaignac,
France
22386 Initial effectiveness and tolerability of nelfinavir (NFV) in combination
with efavirenz (EFV, SUSTIVAT, DMP 266) in antiretroviral therapy naive
or nucleoside analogue experienced HIV-1 infected patients:
Characterization in a phase II, open-label, mult
Elaine Eyster*;J. Jemsek; S. Kagan; G. Martin; D. Seekins; R. Steigbigel;
DJ. Manion, USA
22387 Predictors of maximal viral suppression in clinical practice
Alexandra Moses*; V. Waring; I. Salit; K. Logue; A. Humar; S. Walmsley,
Canada
22388 HIV replication persists in patients receiving HAART despite
undetectable plasma virus
Ven Nata Rajan*; T. W. Chun; D.P. O'Neill;J.A. Metcalf;J. Mican; D. Engel;
A.S. Fauci; H.C. Lane;J.A. Kovacs, USA
22389 Reconstitution of lymph node morphology after advanced AIDS
following antiretroviral triple combination
Johannes Bogner*; C. Jung; C. Ziets; R. Walli; A. Mihlhofer; F.D. Geobel,
Germany

22390 Ritonavir-saquinavir (RTV/SQV) combination in protease inhibitor (PI)
naive and pretreated HIV-infected patients
Ezequiel Consiglio*; D. Podzamczer; F. Bolao; M. Santin;J.L. Perez;
F. Gudiol, Spain
22391 Combination therapy with nelfinavir/saquinavir compared to ritonavir/
saquinavir in protease inhibitor (PI) experienced patients
Valerie E. Stone*; Molly S. Stenzel; S.L. Boswell; V.E. Stone; J. Ng;
A.E. Fisher; K.H. Mayer, USA
22392 Effect of the new antiviral therapy in the quality of life, psychological
profile and economic aspects of the advanced VIH infection
Emilio Pujol*; I. Martin; R. Cano; D.M. Aguayo;J. Galvez; D. Merino;
R. Creagh, Spain
22393 Plasma viral load reduction in an open-label randomized study of
Rescriptor in combination with zidovudine and two dose levels of
indinavir compared to zidovudine, lamivudine, and indinavir in HIV-1
infected individuals
Susie Sargent*; L.K. Wathen; M.F. Para; S.R. Cox; W.W. Freimuth;
C.A. Teugh; D.C. Huang, USA
22394 Changing patterns in use of antiretroviral combination therapy are the
most likely cause of falling AIDS cases and deaths in Scotland
Gwen Allardice*;J.J. McMenamin; G. Codere; T. Parpia; L. Shaw;
D.J. Goldberg; W. Smyth, Scotland
22395 Durable suppression of virus replication with saquinavir in combination
with ritonavir and double nucleoside inhibitor therapy
Martin Markowitz; A. Talal; M.S. Vesanen; Y. Cao; M. Salgo;
M.R. Chaudhry; C. Farthing, USA
22396 Prescriptions of protease inhibitor (PI) antiretroviral (AR) drugs:
Patterns in five large outpatients departments in Rome, Italy
Orlando Armignacco*; P. Narciso; V. Tozzi; P. Sette; P. Franci; R. D'Urso;
F. Montella, Italy
22397 Antiviral effect of a four-drug combination in plasma and lymph node
cells:The "Quadri-96 trial"
Gillese Hittinger*; A. Lafeuillade; C Poggi; L. Chollet; N. Profizi, France
22398 Once-daily therapy (NVP/ddl/3TC) for the IVDU HIV-1 infected
population of the Frankfurt HIV-cohort
Annette Haberl*; P. Gute; A. Carlebach; M. Mdsch; Y. Miller; S. Staszewski,
Germany
22399 Efficacy of antiretroviral (ARV) therapy in Mumbai
Subhash Hira*; H.M. Gharpure; C. Fernandes; C. Jagavkar, India
NOTES

IUNE

CONFERENCE WORKBOOK

93